Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D90UZW
|
|||
| Drug Name |
Ad-RTS-hIL-12
|
|||
| Drug Type |
Gene therapy
|
|||
| Indication | Glioblastoma of brain [ICD-11: 2A00.00; ICD-10: C71] | Phase 2 | [1] | |
| Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 2 | [2] | ||
| Recurrent glioblastoma [ICD-11: 2A00.00; ICD-10: C71] | Phase 2 | [3] | ||
| Malignant glioma [ICD-11: 2A00.0; ICD-9: 191] | Phase 1 | [4] | ||
| Company |
Ziopharm Oncology
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukine 12 (IL-12) | Target Info | Replacement | [5] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04006119) Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma. U.S. National Institutes of Health. | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033476) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 5 | Clinical pipeline report, company report or official report of Ziopharm Oncology. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.